global
viru
network
gvn
establish
strengthen
research
respons
human
viral
diseas
prepar
new
viral
pandem
threat
mann
gvn
center
excel
affili
laboratori
countri
fig
network
scientist
meet
annual
address
research
collabor
prioriti
learn
member
current
work
plan
futur
program
intern
confer
becom
critic
platform
exchang
idea
intern
gvn
meet
held
septemb
melbourn
australia
partnership
peter
doherti
institut
infect
immun
institut
pasteur
brought
togeth
director
gvn
center
colleagu
three
day
scientif
present
discuss
emerg
reemerg
viral
threat
melbourn
meet
first
gvn
event
open
nongvn
scientist
student
investig
clinician
student
area
institut
univers
opportun
attend
scientif
session
present
ongo
student
work
poster
session
expand
opportun
collabor
dialogu
particularli
young
virologist
main
object
meet
present
discuss
current
find
medic
virolog
includ
advanc
fig
gvn
center
excel
associ
laboratori
centr
director
made
signific
contribut
literatur
high
product
term
public
serv
region
resourc
research
diagnost
treatment
program
interact
center
region
outreach
program
less
develop
countri
current
centr
director
list
http
gvnorggvncent
alphaviru
encephalomyel
delin
role
host
immun
respons
viru
clearanc
vaccineinduc
protect
infect
tissu
damag
immun
suppress
dr
griffin
also
cite
leadership
role
within
gvn
intern
confer
virolog
train
program
make
import
basic
scienc
contribut
medic
virolog
award
name
robert
c
gallo
md
cofound
director
homer
martha
gudelski
distinguish
professor
medicin
institut
human
virolog
univers
maryland
school
medicin
cofound
scientif
director
gvn
dr
gallo
cowork
discov
follow
discoveri
first
human
retrovirus
human
tcell
leukemia
colleagu
codiscov
hiv
caus
aid
develop
first
hiv
blood
test
part
formal
gvn
meet
morn
session
infect
chair
damian
purcel
peter
doherti
institut
close
summari
robert
gallo
discuss
publish
gallo
et
al
anticip
addit
public
speaker
forthcom
antoin
gessain
institut
pasteur
pari
review
epidemiolog
origin
genet
divers
eu
commiss
request
european
centr
diseas
prevent
control
ecdc
construct
map
indic
highpreval
area
world
analyz
paper
hundr
abstract
gessain
colleagu
provid
first
complet
epidemiolog
data
map
tabl
world
countri
ecdc
highli
endem
area
mainli
dissemin
maintain
human
popul
intrafamili
transmiss
mothertochild
sexual
intercours
rare
transmiss
may
also
occur
transfus
intraven
drug
use
origin
simian
retroviru
call
simian
tleukemia
viru
type
widespread
old
world
monkey
ape
speci
idea
origin
mainli
base
high
sequenc
homolog
african
subtyp
b
e
f
found
strain
found
individu
includ
hunter
live
centralwest
africa
howev
data
concern
transmiss
human
natura
mode
acquisit
remain
quit
scarc
gessain
also
review
report
case
specul
futur
emerg
virus
simian
foami
virus
gessain
et
al
lloyd
einsiedel
baker
heart
diabet
institut
australia
report
subtyp
c
major
caus
morbid
mortal
among
indigen
australian
viru
highli
endem
central
australia
half
indigen
adult
resid
remot
commun
infect
infect
associ
rapidli
progress
haematolog
malign
adult
tcell
leukemia
atl
inflammatori
diseas
involv
variou
organ
system
increas
likelihood
sever
infect
notabl
strongyloid
stercorali
central
australia
major
diseas
describ
howev
set
infect
often
associ
chronic
respiratori
diseas
includ
lifethreaten
sever
bronchiectasi
invas
bacteri
infect
einsiedel
et
al
region
highest
report
preval
adult
bronchiectasi
among
highest
bloodstream
infect
incid
rate
worldwid
risk
bronchiectasi
extent
pulmonari
injuri
strongli
associ
provir
load
pvl
also
predict
risk
invas
bacteri
infect
associ
pvl
lifethreaten
condit
consist
recent
find
higher
pvl
associ
increas
risk
death
larg
prospect
cohort
indigen
adult
einsiedel
et
al
high
rate
infect
diseas
contribut
substanti
burden
ill
health
earli
mortal
among
indigen
peopl
central
australia
charl
r
bangham
imperi
colleg
uk
note
caus
disabl
chronic
inflammatori
diseas
aggress
rapidli
fatal
malign
adult
tcell
leukemialymphoma
infect
peopl
addit
predispos
exacerb
infect
mycobacterium
tuberculosi
strongyloid
stercorali
staphylococcu
aureu
sever
sometim
fatal
consequ
recent
shown
also
caus
exacerb
bronchiectasi
bronchiti
bronchiol
risk
diseas
strongli
correl
provir
load
frequent
exce
peripher
blood
mononuclear
cell
pbmc
viru
noncytolyt
drive
prolifer
infect
cell
high
provir
load
limit
strong
chronic
activ
cytotox
lymphocyt
ctl
respons
recent
believ
persist
vivo
chiefli
continu
oligoclon
prolifer
clone
cell
howev
bangham
colleagu
shown
typic
individu
carri
clone
provir
loadth
chief
correl
diseasei
determin
number
clone
oligoclon
prolifer
also
believ
latent
vivo
exist
persist
activ
ctl
respons
virtual
host
strongli
argu
viru
latent
frequent
express
suggest
viru
undergo
intermitt
burst
express
vivo
bangham
present
data
singlemolecul
rna
fluoresc
situ
hybrid
smfish
proviru
inde
undergo
intermitt
intens
burst
express
work
way
identifi
factor
regul
frequenc
size
durat
burst
addit
spontan
reactiv
latenc
fresh
pbmc
govern
molecular
oxygen
avail
glycolysi
final
colleagu
discov
alter
host
chromatin
structur
infect
cell
bind
chromatin
architectur
protein
ctcf
regul
higherord
chromatin
structur
gene
express
vertebr
observ
impli
remark
experi
natur
chang
conform
chromatin
ten
thousand
differ
way
infect
host
satou
et
al
studi
way
test
hypothes
ctcf
regul
latenc
abnorm
chromatin
loop
caus
ctcf
deregul
host
gene
express
may
act
oncogen
driver
fabiola
martin
univers
queensland
australia
univers
york
uk
discuss
clinic
diagnosi
treatment
diseas
discoveri
cure
myelopathytrop
spastic
paraparesi
hamtsp
adult
tcell
leukemialymphoma
atll
ongo
process
refin
sinc
earli
martin
present
summari
year
publish
empir
intervent
option
includ
htlv
prevent
strategi
part
intern
htlv
erad
effort
einsiedel
et
al
toshiki
watanab
univers
tokyo
japan
describ
recent
govern
respons
infect
japan
sinc
first
report
atl
takatsuki
group
japanes
clinician
research
made
major
contribut
understand
virolog
pathophysiolog
atl
well
identifi
diseas
hamtsp
uveiti
hu
first
decad
group
japanes
patient
diseas
petit
govern
improv
health
care
treatment
well
continu
strong
support
clinic
basic
research
govern
organ
task
forc
compos
prime
minist
govern
offici
repres
patient
group
medic
specialist
subsequ
nationwid
campaign
began
screen
antibodi
pregnant
women
prevent
new
mothertochild
transmiss
counsel
also
initi
carrier
hamatl
patient
result
steppedup
govern
support
research
care
report
satak
et
al
nosaka
et
al
linfa
wang
dukenu
medic
school
singapor
present
review
year
research
import
bat
natur
reservoir
virus
specif
address
three
question
bat
true
reservoir
emerg
virus
sinc
discoveri
rabi
viru
bat
year
ago
bat
known
carri
zoonot
virus
field
remain
rel
quiet
discoveri
hendra
viru
australian
bat
respons
lethal
outbreak
hors
human
sinc
bat
confirm
suspect
reservoir
sever
emerg
virus
includ
nipah
sar
mer
ebola
marburg
virus
although
scientist
work
field
still
debat
whether
bat
true
reservoir
ebola
viru
exampl
wang
point
took
intern
collabor
team
ten
year
obtain
convinc
evid
bat
origin
sar
coronaviru
ge
et
al
bat
special
abil
host
virus
two
work
hypothes
associ
question
first
difficult
induc
experiment
infect
bat
mani
virus
lethal
human
livestock
second
bat
harbor
virus
per
speci
basi
greater
genet
divers
virus
bat
mammal
evid
gather
support
hypothes
although
base
retrospect
studi
past
literatur
signific
studi
examin
databas
mammalviru
associ
conclud
bat
harbor
significantli
higher
proport
zoonot
virus
mammalian
order
oliv
et
al
make
bat
special
wang
note
bat
long
lifespan
less
prone
cancer
hypothes
evolutionari
adapt
flight
result
uniqu
immun
system
significantli
differ
terrestri
mammal
present
genom
data
indic
robust
posit
select
gene
respons
dna
damag
pathway
zhang
et
al
recent
data
obtain
group
suggest
overal
dampen
inflammatori
respons
may
key
bat
carri
mani
virus
yet
seldom
develop
symptomat
infect
alex
greenwood
leibniz
institut
zoo
wildlif
research
berlin
germani
introduc
concept
exogen
endogen
retrovirus
known
mammalian
genom
compos
endogen
retrovir
element
erv
complet
invas
million
year
ago
obscur
chang
viru
host
associ
koala
retroviru
korv
one
exampl
viru
current
earliest
stage
transit
exogen
retroviru
erv
tarlinton
et
al
go
collect
archiv
sampl
modern
wild
zoo
koala
date
back
greenwood
collabor
found
crucial
earli
event
endogen
involv
recombin
often
mediat
exist
retrovirallik
element
alreadi
resid
host
genom
recombin
event
disabl
exogen
retroviru
make
less
potenti
harm
host
time
ancient
retrovirallik
element
may
reestablish
activ
propag
retroel
hobb
et
al
context
tri
find
origin
korv
greenwood
et
al
confirm
close
relationship
gibbon
ape
leukemia
viru
galv
like
recent
interspeci
transmiss
phylogenet
two
rodent
virus
melomi
bertoni
retroviru
mbrv
melomi
woolli
monkeylik
viru
melwmv
closest
korvgalvlik
virus
identifi
date
alfano
et
al
greenwood
conclud
close
rel
korvgalv
circul
varieti
mammalian
taxa
within
australopapuan
region
east
wallac
line
lorena
brown
univers
melbourn
australia
present
new
concept
antivir
drug
design
current
antivir
strategi
tend
target
specif
viral
protein
inhibit
function
brown
describ
antivir
drug
modular
structur
consist
viral
attach
domain
effector
domain
gener
attach
domain
antibodi
domain
motif
structur
bind
surfac
viru
effector
domain
vari
enzym
charg
cloud
collabor
au
bio
ltd
concept
test
influenza
viru
entri
influenza
viru
cell
receptormedi
endocytosi
environ
endosom
becom
acid
viral
hemagglutinin
ha
undergo
conform
chang
reveal
hydrophob
fusion
region
penetr
endosom
membran
thu
initi
life
cycl
viru
replic
insid
cell
candid
drug
molecul
use
attach
domain
bind
ha
effector
domain
provid
negativelycharg
environ
trigger
prematur
conform
chang
neighbour
ha
prevent
viral
replic
brown
present
vivo
data
two
drug
provid
better
protect
mous
ferret
model
zanamivir
construct
appear
provid
extend
therapeut
window
adapt
immun
system
come
play
longdur
activ
drug
suggest
may
use
prophylaxi
especi
pandem
context
soren
alexandersen
geelong
centr
emerg
infecti
diseas
australia
describ
outbreak
sever
infect
among
australian
infant
caus
recombin
strain
human
parechoviru
type
human
parechoviru
type
positivestrand
rna
virus
type
parechoviru
caus
sever
diseas
infant
mortal
potenti
longterm
sequela
newli
recogn
diseas
infant
diagnost
test
avail
australia
investig
outbreak
found
genom
australian
virus
undergon
major
recombin
event
took
place
march
novemb
follow
viru
evolut
possibl
recombin
phylogenet
network
analys
geelong
group
support
tempor
evolut
first
australian
recombin
viru
sequenc
novemb
marchapril
outbreak
data
show
outbreak
virus
recombin
yamagata
lineag
yet
unknown
viru
nelson
et
al
unknown
viru
donor
nonstructur
code
region
may
come
notyet
sequenc
human
parechoviru
altern
potenti
unknown
anim
sourc
similar
virus
infect
anim
recombin
detect
pig
south
america
nix
et
al
final
alexandersen
observ
outbreak
seem
follow
cycl
suggest
may
anoth
wave
outbreak
australia
nobel
laureat
peter
doherti
peter
doherti
institut
infect
immun
australia
provid
review
cytotox
lymphocyt
contribut
antivir
immun
human
famili
constantli
challeng
virus
epidemicpandem
pathogen
either
emerg
wildlif
domest
anim
reservoir
consequ
immun
escap
mutat
strain
circul
us
vaccin
promot
longterm
antibodymedi
immun
mop
invad
provid
immedi
protect
though
cours
doherti
note
product
someth
new
unexpect
hit
intim
parasit
virus
grow
within
live
cell
consequ
part
process
recoveri
requir
elimin
cellular
factori
pathogen
product
hit
man
immun
job
circul
white
blood
cell
virusspecif
killer
tcell
cytotox
tlymphocyt
ctl
ctl
target
cell
surfac
via
recognit
viral
peptid
bound
self
mhc
class
glycoprotein
recent
find
concern
hla
type
influenza
prevent
suscept
particular
interest
especi
regard
greater
suscept
indigen
popul
influenza
bessaud
institut
pasteur
pari
review
genet
recombin
among
positivestrand
rna
virus
suggest
enterovirus
conveni
model
vitro
studi
recombin
particular
mostli
nonhomolog
recombin
genom
seen
genom
delet
duplic
subsequ
evolv
homolog
recombin
genom
region
recombin
occur
frequent
identifi
hotspot
bound
genom
domain
consid
modul
use
engend
new
mosaic
genom
recombin
result
illustr
recombin
abl
gener
wide
genet
phenotyp
divers
promot
emerg
new
virus
joaquim
segal
centr
de
recerca
en
sanitat
anim
spain
describ
dromedari
camel
model
middl
eastern
respiratori
syndrom
coronaviru
merscov
infect
experiment
intranas
inocul
merscov
produc
upper
respiratori
tract
infect
urt
mild
clinic
sign
infecti
viru
detect
trachea
larg
bronchi
tracheobronchi
lymph
node
viral
rna
wide
detect
nose
upper
lower
respiratori
tract
extrapulmonari
lymphoid
viscer
tissu
nasal
tracheal
bronchial
inflamm
present
without
gross
lesion
similar
clinicalpatholog
pictur
seen
intranas
merscov
inocul
domest
new
world
camelid
produc
either
clinic
sign
alpaca
mild
mucu
secret
llama
merscov
detect
urt
nasal
swab
trachea
speci
clear
urt
day
postinfect
concomit
antibodi
respons
pig
also
may
experiment
infect
show
presenc
viral
rna
nasal
swab
trachea
bronchi
day
postinocul
limit
transmiss
direct
contact
mate
seen
experiment
condit
experi
perform
date
suggest
larg
anim
domest
speci
hors
sheep
goat
suscept
merscov
infect
ramesh
akkina
colorado
state
univers
usa
describ
new
improv
human
mous
humous
model
harbor
transplant
human
immun
system
studi
viral
pathogenesi
evolut
latenc
human
immun
respons
hiv
dengu
zika
virus
schmitt
et
al
outlin
use
humic
altern
vitro
viral
outgrowth
assay
qvoa
current
gold
standard
measur
latent
hiv
cure
research
often
fail
detect
low
level
replicationcompet
viru
evidenc
boston
patient
hayden
akkina
show
humic
also
provid
potenti
anim
model
studi
test
threedrug
formul
antiretrovir
hu
et
al
humic
suscept
infect
show
persist
viremia
tcell
loss
key
hallmark
aid
pathogenesi
akkina
also
describ
ideal
anim
model
human
cell
infect
human
immun
respons
lack
flavivirus
dengu
zika
dengu
pathogenesi
studi
humic
shown
permiss
product
infect
result
viremia
last
three
week
fevercharacterist
denguewa
note
infect
mice
develop
human
neutral
antidengu
igm
igg
antibodi
recent
experi
show
humic
blt
mice
also
suscept
zika
viru
chronic
viremia
last
day
virusinfect
human
monocytesmacrophag
b
cell
hematopoiet
stem
cell
found
bone
marrow
schmitt
et
al
human
neutral
antibodi
detect
highlight
use
model
futur
vaccin
test
peter
revil
doherti
institut
melbourn
describ
intern
coalit
elimin
hepat
b
viru
icehbv
establish
acceler
research
cure
hepat
b
infect
vision
icehbv
develop
intern
independ
researchbas
patientcent
forum
coordin
promot
foster
collabor
partnership
work
toward
cure
chronic
hepat
b
chb
million
peopl
worldwid
chronic
infect
hbv
even
though
prophylact
vaccin
effect
antivir
therapi
avail
postinfect
cure
exist
concern
asiapacif
region
million
peopl
includ
australian
live
chb
recent
advanc
field
identif
ntcp
receptor
viral
entri
improv
cell
cultur
anim
model
facilit
new
era
cure
research
worldwid
watashi
et
al
revil
et
al
global
network
icehbv
work
promot
research
collabor
aim
develop
cure
quickli
possibl
liz
bannist
royal
melbourn
hospit
australia
note
children
world
poorest
countri
often
vaccin
hbv
includ
much
africa
million
peopl
chronic
infect
immigr
peopl
highli
endem
region
includ
subsaharan
africa
australia
hbv
preval
continu
rise
furthermor
african
hbv
genotyp
natur
histori
african
chb
remain
poorli
character
particularli
children
african
chb
associ
uniqu
genotyp
e
although
preval
genotyp
outsid
australia
poorli
describ
bannist
colleagu
found
hbv
genotyp
african
children
adult
live
melbourn
larg
reflect
countri
origin
includ
genotyp
associ
rapid
progress
hepatocellular
carcinoma
reduc
vaccin
efficaci
recombin
virus
earli
eantigen
seroconvers
observ
hbv
variant
previous
associ
sever
clinic
diseas
progress
seen
around
children
adulthood
vitro
studi
genotyp
show
differ
way
african
clone
replic
produc
viral
protein
may
implic
strain
produc
diseas
treat
find
import
ramif
patient
monitor
treatment
guidelin
particularli
pediatr
set
australia
shyamasundaran
kottilil
institut
human
virolog
usa
report
chronic
hepat
c
viru
hcv
infect
affect
approxim
million
peopl
worldwid
major
caus
morbid
liver
cancer
liver
transplant
mortal
current
goal
hcv
therapi
achiev
function
cure
defin
sustain
virolog
respons
svr
detect
plasma
hcv
rna
detect
week
therapi
recent
oral
directact
antivir
daa
therapi
shown
safe
toler
highli
effect
achiev
svr
without
use
interferonalpha
associ
advers
event
long
durat
modest
svr
major
mileston
manag
chronic
hepat
c
still
peopl
infect
hcv
awar
statu
twenti
percent
care
less
ten
percent
treat
greater
awar
among
provid
patient
requir
optim
care
continuum
approach
enabl
increas
patient
screen
effect
taskshift
care
develop
pointofcar
test
strategi
margin
patient
critic
achiev
elimin
hepat
c
infect
mathur
et
al
hiv
hcv
import
global
viral
pathogen
landscap
prevent
vaccin
cure
drug
treatment
chang
substanti
glenda
gray
south
african
medic
research
council
provid
updat
current
hiv
vaccin
efficaci
trial
although
antiretrovir
treatment
art
highli
success
expens
lead
drug
resist
difficult
fulli
implement
half
hiv
infect
transmit
subject
within
first
month
infect
often
awar
infect
wide
recogn
hiv
vaccin
essenti
tool
control
hiv
epidem
especi
region
high
preval
southern
africa
last
year
hiv
vaccin
strategi
evolv
simpl
protein
approach
singl
vector
design
induc
cytotox
cell
toward
heterolog
primeboost
regimen
design
induc
broader
immun
thai
rv
trial
canarypox
protein
prime
boost
vaccin
regiment
show
efficaci
rerksngarm
et
al
subject
hvtn
trial
way
see
improv
upon
efficaci
time
gvn
meet
subject
alreadi
enrol
twostag
followup
trial
plan
determin
efficaci
durabl
gray
also
report
plan
second
primeboost
efficaci
trial
southern
africa
hvtn
trial
use
adenoviru
type
boost
regimen
well
advanc
regimen
show
signific
efficaci
monkey
trial
barouch
et
al
announc
subsequ
gvn
meet
trial
go
ahead
wwwnihgovnewseventsnewsreleas
nihpartnerslaunchhivvaccineefficacystudi
separ
primeboost
vaccin
efficaci
trial
anoth
efficaci
trial
passiv
transfer
monoclon
neutral
antibodi
way
south
africa
north
america
hvtn
studi
antibodi
effect
prevent
infect
monkey
model
reduc
hiv
level
infect
human
gray
et
al
lynch
et
al
damian
purcel
doherti
instituteunivers
melbourn
provid
updat
approach
hiv
cure
hiv
remain
latent
despit
art
mean
treatment
must
continu
life
latent
hiv
reactiv
certain
drug
activ
viru
transcript
histon
deacetylas
inhibitor
hope
reactiv
viru
clear
socal
shock
kill
strategi
deek
howev
recent
clinic
trial
drug
show
effect
modest
effect
gene
transcript
nonspecif
prolong
sogaard
et
al
newer
specif
effect
less
toxic
altern
need
purcel
group
develop
assay
measur
transcript
hiv
mediat
specif
tat
lend
highthroughput
screen
inhibitor
describ
novel
class
drug
amidothiazol
appear
specif
activ
tatmedi
hiv
transcript
tcell
line
minim
toxic
precis
target
mode
action
studi
abil
reactiv
hiv
blood
sampl
infect
peopl
promis
approach
ultim
expand
armamentarium
potenti
hivcur
drug
margaret
hellard
burnet
institut
melbourn
present
effort
group
collabor
elimin
hcv
transmiss
multiprong
effort
cure
larg
number
patient
efficaci
simplic
newer
daa
hepat
c
provid
window
reduc
transmiss
reduc
number
virem
subject
model
show
highli
effect
strategi
long
suffici
number
peopl
risk
transmit
hcv
treat
cost
newer
drug
come
mani
part
world
australia
approach
univers
access
facilit
larger
scale
treatment
uptak
increas
rapid
test
hcv
assess
liver
fibrosi
treatment
administ
transmiss
network
commun
like
requir
achiev
goal
pedrana
et
al
arbovirus
wide
distribut
viral
pathogen
also
caus
frequent
episod
epidem
diseas
mani
factor
contribut
emerg
spread
virus
includ
global
chang
vector
compet
climat
chang
spillov
event
affect
vector
ensu
victim
gould
et
al
session
provid
research
inform
rang
mosquito
control
intervent
epidemiolog
understand
vaccin
virushost
interact
cameron
simmon
univers
melbourn
australia
describ
past
present
difficulti
control
dengu
viru
denv
infect
global
highlight
strategi
current
employ
mosquito
limit
replic
transmiss
mani
arboviru
infect
includ
denv
detail
current
approach
employ
world
mosquito
program
wmp
previous
known
elimin
dengu
establish
intracellular
bacterium
wolbachia
mosquito
popul
wolbachia
bacterium
intriguingli
abil
limit
viru
replic
coinfect
cell
moreira
et
al
wolbachiaharbour
mosquito
success
deploy
around
cairn
australia
wmp
initi
similar
program
denvendem
area
indonesia
brazil
columbia
vietnam
india
simmon
underlin
challeng
wmp
includ
commun
local
popul
cost
largescal
implement
measur
mileston
evidencebas
outcom
develop
method
measur
impact
wolbachia
diseas
incid
still
current
result
project
look
encourag
approach
limit
arboviru
infect
scott
weaver
univers
texa
medic
branch
galveston
usa
chair
gvn
task
forc
zika
viru
zikv
provid
time
updat
dramat
emerg
zikv
south
central
america
histor
view
spread
zikv
africa
asia
south
pacif
america
aliota
et
al
weaver
describ
manifest
diseas
human
syndrom
microcephali
signific
impact
infect
unborn
fetu
infect
pregnant
women
one
interest
recent
observ
precipit
declin
report
zika
case
reason
current
unclear
though
increas
herd
immun
may
factor
weaver
highlight
recent
advanc
zikv
research
emphasis
larg
volum
research
dedic
past
year
culmin
numer
vaccin
candid
clinic
trial
develop
nonhuman
primat
model
investig
pathogenesi
one
import
consider
studi
potenti
crossreact
flaviviru
antibodi
particularli
either
denv
zikv
enhanc
denvzikv
diseas
subsequ
infect
identifi
mani
research
gap
still
remain
particularli
diagnosi
mani
current
diagnost
test
crossreact
develop
specif
zikv
kit
look
encourag
gvn
support
zikv
serum
bank
aid
develop
better
diagnost
addit
propos
herd
immun
gener
zikv
caribbean
latin
america
may
hinder
develop
vaccin
difficult
assess
candid
vaccin
popul
market
vaccin
absenc
signific
new
case
ferguson
et
al
principl
underli
uniqu
pathogenesi
transmiss
rout
zikv
still
remain
unansw
robert
garri
tulan
medic
school
usa
discuss
develop
antibodi
lassa
fever
viru
lasv
ebola
viru
ebov
provid
overview
histori
two
virus
effort
coordin
establish
collabor
network
provid
outreach
educ
affect
african
commun
yozwiak
et
al
describ
gener
human
monoclon
antibodi
cocktail
target
lasv
glycoprotein
technolog
avail
produc
larg
quantiti
highli
specif
human
monoclon
proven
effect
nonhuman
primat
model
mire
et
al
develop
construct
bival
trival
vaccin
candid
express
stabil
lasv
ebov
glycoprotein
encourag
tool
lethal
haemorrhag
fever
virus
marc
lecuit
biolog
infect
unit
institut
pasteur
inserm
franc
describ
role
cellular
unfold
protein
respons
upr
develop
zikv
diseas
present
evid
upr
contribut
neurogenesi
upregul
upr
neuron
progenitor
cell
impact
develop
result
microcephali
mous
model
show
compel
data
indic
zikv
induc
upr
neuron
progenitor
cell
reflect
dysregul
neuron
develop
reduc
brain
mass
zikvinfect
fetal
mice
gladwynng
et
al
therapeut
intervent
allevi
upr
reduc
present
microcephali
zikvinfect
mice
offer
possibl
therapeut
strategi
area
gladwynng
et
al
john
fazakerley
peter
doherti
institut
infect
immun
australia
report
european
unionfund
integr
chikungunya
research
icr
programm
icr
consist
intern
laboratori
work
develop
new
molecular
cellular
tool
studi
chikungunya
viru
understand
virusvector
relationship
develop
new
diagnost
antivir
vaccin
advanc
understand
pathogenesi
diseas
sequela
also
present
two
studi
experiment
anim
model
investig
whether
alphaviru
semliki
forest
viru
caus
enceph
persist
brain
whether
alphaviru
chikungunya
viru
caus
arthralgia
persist
joint
massimo
palmarini
gvn
centr
director
mrcunivers
glasgow
scotland
report
innat
immun
respons
mediat
type
interferon
ifn
result
upregul
hundr
ifnstimul
gene
isg
interferom
provid
immedi
barrier
viru
infect
studi
type
ifn
respons
mainli
carri
singlespeci
level
often
lack
compar
power
necessari
understand
key
evolutionari
featur
pathway
palmarini
colleagu
determin
common
uniqu
properti
interferom
multipl
vertebr
speci
develop
open
access
webserv
mine
dataset
report
find
core
isg
includ
gene
previous
associ
ifn
underscor
ancestr
function
associ
type
ifn
respons
show
gene
expans
contribut
evolut
ifn
system
interferom
shape
lineagespecif
pressur
furthermor
analysi
gene
commonli
downregul
ifn
suggest
epigenet
regul
transcript
fundament
aspect
ifn
respons
joshua
hayward
burnet
institut
australia
note
viral
infect
bat
typic
produc
sign
clinic
diseas
rais
question
innat
immun
differ
might
exist
bat
mammal
gene
famili
encod
antivir
dna
cytosin
deaminas
restrict
factor
import
role
suppress
divers
virus
genom
parasit
hayward
colleagu
character
megabat
famili
pteropodida
gene
show
pteropid
bat
possess
largest
divers
array
gene
identifi
mammal
report
date
sever
bat
protein
shown
capabl
restrict
retrovir
infect
use
model
hypermut
analysi
endogen
retrovirus
p
vampyru
support
role
restrict
ancient
bat
retrovirus
molecular
clock
analysi
indic
expans
gene
coincid
extinct
pteropid
retroel
hayward
et
al
find
reveal
first
group
antivir
restrict
factor
identifi
bat
extens
diversif
diverg
rel
homologu
mammal
didier
fontenil
institut
pasteur
du
cambodg
describ
divers
arboviru
vector
asia
differ
mosquito
speci
identifi
thailand
vietnam
cambodia
respect
littl
known
tick
howev
even
less
sandfli
bite
midg
compar
divers
vector
arbovirus
identifi
beyond
big
four
dengu
viru
serotyp
japanes
enceph
viru
chikungunya
viru
recent
zika
viru
strategi
vector
control
asian
countri
fewwith
rare
success
numer
failur
appear
sever
reason
vector
control
stalem
includ
pauciti
field
research
well
lack
interest
andor
compet
research
laboratori
fontenil
pose
number
question
region
emerg
new
virus
ask
effect
control
vector
assess
risk
emerg
outbreak
within
frame
environment
social
climat
chang
know
biolog
evolut
mosquito
exampl
ae
aegypti
vs
ae
albopictu
mosquitoviru
coadapt
asia
southeast
asia
expect
emerg
zika
viru
fontenil
review
issu
made
recommend
activ
holist
research
approach
involv
virologist
zoologist
ecologist
social
scientist
oftenneglect
entomologist
roch
et
al
anthoni
l
cunningham
univers
sydney
australia
describ
find
eat
signal
attract
human
dermal
dendrit
cell
ddc
langerhan
cell
lc
infect
herp
simplex
viru
hsv
facilit
recognit
uptak
apoptot
lc
bot
et
al
colleagu
assess
express
chemokin
hsvinfect
lc
correspond
chemokin
receptor
ddc
subset
well
apoptot
receptor
may
recogn
facilit
interact
studi
help
defin
mechan
uptak
viral
antigen
transfer
lc
ddc
lead
subsequ
differenti
present
tcell
may
defin
potenti
dendrit
cell
target
adjuv
futur
mucos
intraderm
vaccin
zhiwei
chen
aid
institut
depart
microbiolog
hong
kong
sar
china
report
hiv
enteropathi
acut
hiv
infect
character
diarrhea
gastrointestin
inflamm
increas
intestin
permeabl
malabsorpt
nutrient
inflammatori
mediat
infiltr
activ
tcell
proinflammatori
cytokin
tcell
deplet
like
contribut
chang
intestin
follow
local
immun
activ
chen
colleagu
discov
subset
gammadelta
tcell
also
may
contribut
innat
immun
activ
mucos
damag
acut
hiv
infect
cheung
et
al
cell
may
serv
target
investig
diseas
mucos
inflamm
addit
initi
hiv
infect
mucos
surfac
bonni
howel
merck
boston
usa
describ
import
elucid
mechan
persist
develop
innov
strategi
treatment
function
cure
class
small
moleculeshiston
deacetylas
inhibitor
hdaci
studi
latencyrevers
agent
clinic
studi
shown
singl
multipl
administr
result
induc
viral
rna
transcript
protein
tcell
artsuppress
hiv
subject
furthermor
appli
novel
screen
strategi
latenc
revers
agent
presenc
sensit
agent
hdaci
use
approach
identifi
new
mechan
altern
therapi
latenc
intervent
notabl
explor
cure
strategi
target
latent
hiv
reservoir
also
highlight
need
new
assay
research
tool
quantifi
viral
burden
tissu
variou
bodi
fluid
rare
incid
latentlyinfect
cell
robust
phenotyp
marker
still
need
present
challeng
identifi
cell
measur
chang
viral
express
particularli
therapeut
intervent
sarah
palmer
centr
viru
research
univers
sydney
australia
report
fulllength
hiv
sequenc
techniqu
reveal
major
persist
hiv
proviru
cell
genet
defect
antiretrovir
therapi
hiener
et
al
howev
distribut
intact
provirus
within
memori
tcell
subset
particip
initi
therapi
either
acut
chronic
infect
show
proport
intact
proviru
significantli
differ
across
cell
subset
cell
express
hladr
activ
marker
effector
memori
cell
contain
highest
proport
intact
hiv
genom
addit
clonal
expans
intact
provirus
identifi
indic
prolifer
cell
contribut
latent
reservoir
hladr
marker
identifi
cell
contain
high
frequenc
intact
hiv
genom
therefor
assay
quantifi
persist
hiv
reservoir
includ
cell
determin
type
cell
cellular
mechan
contribut
persist
replicationcompet
hiv
crucial
futur
effort
aim
hiv
erad
ricki
mentha
baker
heart
diabet
research
institut
australia
report
aborigin
popul
resid
remot
locat
limit
gener
knowledg
infecti
diseas
mode
transmiss
prevent
public
health
measur
exposur
array
communic
diseas
preval
morbid
mortal
signific
effect
partnership
local
aborigin
stakehold
critic
improv
knowledg
infecti
diseas
develop
prevent
strategi
deriv
wellthoughtout
research
agenda
mentha
describ
mani
press
need
includ
research
ground
principl
social
justic
equiti
commun
consult
partnership
build
capac
aborigin
research
commun
member
translat
find
polici
practic
health
promot
mani
complex
address
conduct
communic
diseas
research
remot
aborigin
popul
done
ethic
cultur
sensit
way
contribut
reduc
exposur
povertyrel
infecti
diseas
impact
morbid
mortal
brown
et
al
kanta
subbarao
collabor
centr
refer
research
influenza
australia
present
recent
data
replic
viral
properti
govern
airborn
transmiss
influenza
viru
pandem
ferret
transmiss
model
describ
complex
viral
host
interact
influenc
transmiss
phenotyp
influenza
virus
sutton
et
al
frederick
kristensen
cepi
oslo
norway
describ
recent
establish
coalit
epidem
prepared
innov
cepi
organ
launch
januari
initi
invest
million
provid
govern
norway
japan
germani
bill
melinda
gate
foundat
wellcom
trust
addit
european
commiss
agre
cofund
cepi
project
million
fund
avail
australia
belgium
canada
launch
cepi
issu
call
propos
develop
vaccin
three
viral
agent
merscoronaviru
lassa
nipah
viru
new
call
plan
develop
vaccin
platform
octob
christian
md
phd
becam
new
gvn
presid
http
gvnorgbrechot
previous
serv
presid
institut
pasteur
pari
dr
held
leadership
posit
french
nation
institut
health
medic
research
inserm
institut
bioaster
technolog
research
institut
previous
serv
univers
professor
hospit
practition
head
depart
hepatolog
cell
biolog
dr
receiv
doctor
medicin
pari
descart
univers
pari
vii
phd
biochemistri
pari
descart
univers
throughout
career
research
focus
hbv
hcv
particularli
regard
role
liver
cancer
molecular
mechan
drive
liver
regener
cancer
member
numer
scientif
committe
societi
receiv
myriad
prestigi
award
dr
author
articl
medic
scientif
journal
new
chang
gvn
headquart
staff
sever
activ
continu
includ
collect
acut
convalesc
sera
confirm
zika
patient
aid
develop
new
diagnost
serum
bank
fund
grant
allergan
foundat
sampl
store
univers
texa
medic
branch
galveston
texa
addit
shyamasundran
kottilil
colleagu
institut
human
virolog
baltimor
continu
project
gvn
expand
train
model
health
care
provid
use
daa
treatment
hepat
c
patient
india
mathur
et
al
train
program
fund
gilead
foundat
similarli
pilot
studi
develop
integr
clinic
databas
support
communitybas
care
hepat
b
patient
arunach
pradesh
india
also
way
fund
john
c
martin
foundat
gvn
task
forc
member
publish
commentari
recommend
current
name
chang
back
origin
name
human
tcell
leukemia
keep
oncogen
pathogenesi
gvn
investig
publish
work
oncogen
member
gvn
task
forc
zika
viru
also
publish
major
review
learn
zika
first
two
year
epidem
america
gap
remain
aliota
mt
et
al
network
expand
number
cooper
research
center
ad
foundat
lyon
franc
rega
institut
medic
research
univers
leuven
belgium
fig
two
new
center
expect
strengthen
research
vaccin
collabor
activ
develop
countri
gvn
staff
continu
solicit
patient
serum
sampl
zika
serum
bank
galveston
texa
addit
project
sequenc
conduct
phylogenet
analys
collect
zika
viru
isol
continu
cooper
world
refer
centr
emerg
virus
arbovirus
wrceva
fund
nation
institut
allergi
infecti
diseas
usa
gvn
host
fifth
annual
short
cours
medic
virolog
young
investig
summer
short
cours
attract
intern
class
postdoctor
student
fellow
five
day
meet
lectur
expert
medic
virolog
research
clinic
practic
inform
cours
registr
avail
onlin
http
gvnorg
intern
gvn
meet
anneci
franc
novemb
cohost
research
centr
emerg
infect
zoonos
univers
veterinari
medicin
hanov
germani
